CytRx Corp. buy melinda
Start price
11.05.17
/
50%
€2.41
Target price
18.05.17
€3.25
Performance (%)
14.13%
End price
18.05.17
€2.75
Summary
This prediction ended on 18.05.17 with a price of €2.75. The prediction had a final performance of 14.13%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | -1,36 % | -2,33 % | 3,44 % | 53,51 % |
| iShares Nasdaq 100 | -3,70 % | -1,24 % | 33,08 % | 90,97 % |
| iShares Nikkei 225® | -2,51 % | 6,91 % | 60,78 % | 81,10 % |
| iShares S&P 500 | -1,66 % | -0,64 % | 23,47 % | 67,07 % |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Aldoxorubicine mit Doxorubicin
Krebs Weichteilsarkom feuerfester Krebs